Naturex SA has acquired Swedish Oat Fiber AB
November 2017 — Naturex SA, the global leader in specialty plant-based natural ingredients, has acquired Swedish Oat Fiber AB, a specialized manufacturer of oat dietary fibers, oat oils and oat proteins. Financial details have not been disclosed.
Naturex sources, manufactures and markets natural specialty ingredients for the food, healthcare and cosmetic industries. Headquartered in Avignon, France, the group has experienced steadily increasing growth throughout the last 25 years. Naturex employs 1,700 people worldwide and had revenues of US$437 million in 2016.
Swedish Oat Fiber is a manufacturer with a key international position as a producer of oat beta-glucans dietary fibers, oat oils and oat proteins for the food industry, nutraceutical, cosmetic and animal feed applications. The company has 25 employees and an annual turnover of US$13.2 million.
Our role in the transaction
Oaklins' teams in France and Sweden identified potential targets and advised the buyer on this transaction. This is another example of the strength of Oaklins' teams working together.
Talk to the deal team
Related deals
KPS Food Group has joined ForFarmers Polska, a joint venture controlled by ForFarmers N.V.
ForFarmers N.V. has strengthened its position in Poland’s growing poultry market through the establishment of a joint venture with KPS Food Group, a leading poultry producer with operations spanning farming, slaughtering and food processing. ForFarmers’ existing Polish joint venture, Tasomix, and KPS’s operations have been combined to form ForFarmers Polska, which has an enterprise value of approximately US$585 million. ForFarmers holds a controlling 50.5% stake and will fully consolidate the joint venture. The founders of KPS and Tasomix remain minority shareholders.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more